Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
trade secrets
Pharma
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Akeso and Summit's ivonescimab handily beat Keytruda in a China phase 3 study. The House passed the BIOSECURE Act. Candid emerged with $370 million.
Angus Liu
Sep 13, 2024 8:53am
Novartis, Neurocrine-Takeda, Enhertu—Fierce Pharma Asia
Apr 26, 2024 5:45am
FibroGen, Kind Pharma settle trade secrets theft dispute
Apr 19, 2024 12:53pm
Leqembi, Takeda, Fujifilm Diosynth—Fierce Pharma Asia
Apr 19, 2024 9:20am
J&J sues ex-staffer for allegedly taking secret docs to Pfizer
Mar 21, 2024 9:08am
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
